Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises

  1. Frankie B. Stentz,
  2. Guillermo E. Umpierrez,
  3. Ruben Cuervo and
  4. Abbas E. Kitabchi
  1. From the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
  1. Address correspondence and reprint requests to Frankie B. Stentz, PhD, Assistant Professor, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Tennessee Health Science Center, 951 Court Ave., Room 340M, Memphis, TN 38163. E-mail: fstentz{at}utmem.edu
Diabetes 2004 Aug; 53(8): 2079-2086. https://doi.org/10.2337/diabetes.53.8.2079
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
    • Download figure
    • Open in new tab
    • Download powerpoint
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    The proinflammatory cytokine levels of IL-8 (A), IL-6 (B), TNF-α (C), and IL-1β (D) measured in the plasma at admission and resolution of the patients in hyperglycemic crisis. The bar graphs show the means ± SE for each of the patient groups: lean DKA (n = 20); obese DKA (n = 28); obese hyperglycemic (n = 10); and lean and obese control subjects (n = 12 each). ☆The admission and resolution levels are significantly different (P ≤ 0.01), and the admission levels are significantly different from the control subjects.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Markers of oxidative stress and cardiovascular risk markers determined in the plasma of the patient groups at admission and resolution of hyperglycemic crisis. The graphs show the means ± SE for each of the patient groups for each of the markers: high-sensitivity CRP, FFAs, homocysteine, DCF reactive, PAI-1, and TBA reactive. ▴, lean DKA (n = 20); ♦, obese DKA (n = 28); •, obese hyperglycemic (n = 10); and ×, lean; □, obese control subjects (n = 12 each). All markers were significantly different at admission compared with at resolution of hyperglycemic crisis except for homocysteine, where only the lean DKA values were significantly different.

Tables

  • Figures
  • TABLE 1

    Clinical characteristics of hyperglycemic patients on admission

    ParametersLean DKAObese DKAObese hyperglycemiaLean controlObese control
    Patients (n)2028101212
    Age (years)39 ± 2.738 ± 2.050 ± 3.735.7 ± 1.936.5 ± 3.1
    Sex (M/F)13/720/85/57/54/8
    BMI (kg/m2)22 ± 0.633 ± 0.9*30 ± 0.9*22 ± 0.734 ± 1.6*
    Temperature (°F)97.3 ± 0.597.2 ± 0.398.3 ± 0.298.4 ± 0.198.5 ± 0.2
    HbA1c12.5 ± 0.411.6 ± 0.410.8 ± 0.65.4 ± 0.5*5.7 ± 0.7*
    White blood cell × 10614.4 ± 0.714.2 ± 1.311.8 ± 2.06.5 ± 0.7*6.8 ± 0.6*
    • Data are means ± SE.

    • *

      * P < 0.01 vs. lean DKA on admission.

  • TABLE 2

    Laboratory values at admission and resolution of patients in hyperglycemic crisis

    Lean DKA
    Obese DKA
    Obese hyperglycemia
    Lean controlObese control
    AdmissionResolutionAdmissionResolutionAdmissionResolution
    Blood glucose (mg/dl)766 ± 72176 ± 10*743 ± 60184 ± 16*690 ± 66186 ± 22*92 ± 1.5*93 ± 1.7*
    Serum HCO3 (mEq/l)6.0 ± .820.9 ± .6*8.3 ± .620.5 ± .6*25 ± .7*25.6 ± 1.1*26 ± 1.0*26 ± 1.5*
    Venous pH7.09 ± .037.35 ± .017.17 ± .027.33 ± .01*7.34 ± .047.43 ± .01——
    Osmolality (mOsm/kg)310 ± 4.3293 ± 3.1*317 ± 5.0294 ± 4.0*311 ± 9.8289 ± 5.0*285 ± 6.0*286 ± 5.0*
    β-Hydroxybutyrate (mmol/l)10.6 ± .70.8 ± .2*8.7 ± .61.2 ± .2*0.5 ± .04*0.3 ± .03*0.1 ± .02*0.1 ± .03*
    Cortisol (μg/dl)46.2 ± 2.321.7 ± 1.1*55.4 ± 5.824.6 ± 3.6*23 ± .9*17.2 ± 1.4*14 ± 1.2*13 ± 1.1*
    GH (ng/ml)12.3 ± 2.23.2 ± 1.0*10.0 ± 3.14.0 ± 1.2*1.6 ± .3*0.9 ± .2*0.8 ± .2*0.8 ± .2*
    C-peptide (ng/ml)0.8 ± .10.7 ± .11.5 ± .2*0.8 ± .12.5 ± .3*1.3 ± .40.9 ± .21.2 ± .3
    • Data are means ± SE.

    • *

      * P < 0.01 vs. lean DKA on admission.

  • TABLE 3

    Markers of cardiovascular risks and oxidative stress at admission and resolution of hyperglycemic crisis

    Lean DKA
    Obese DKA
    Obese hyperglycemia
    Lean controlObese control
    AdmissionResolutionAdmissionResolutionAdmissionResolution
    CRP (mg/l)51 ± 328 ± 1*†59 ± 1334 ± 9*†28 ± 613 ± 3*†1 ± 0.2*†2 ± 0.4*†
    Homocysteine (μmol/l)18.8 ± 0.814.8 ± 0.7*†23.6 ± 3.621.6 ± 2.814.8 ± 1.612.4 ± 1.2*7.2 ± 0.4*†8.8 ± 1.2*†
    FFA (mmol/l)1.6 ± 0.10.6 ± 0.1*†1.4 ± 0.10.7 ± 0.1*†1.2 ± 0.20.8 ± 0.1*†0.5 ± 0.1*†0.7 ± 0.1*†
    DCF (μmol/l)8.6 ± 0.83.7 ± 0.5*†8.9 ± 1.24.1 ± 0.7*†7.8 ± 0.63.8 ± 0.5*†2.3 ± 0.4*†3.1 ± 0.6*†
    TBA (μmol/l)3.8 ± 0.71.3 ± 0.4*†4.0 ± 0.61.6 ± 0.2*†3.3 ± 0.51.5 ± 0.4*†0.8 ± 0.1*†0.9 ± 0.1*†
    PAI-1 (ng/ml)42.1 ± 12.24.2 ± 2.1*†40.4 ± 12.413.0 ± 3.4*†35.4 ± 9.37.3 ± 2.4*†1.4 ± 0.2*†2.5 ± 0.4*†
    • Data are means ± SE.

    • *

      * P < 0.01 vs. lean DKA on admission;

    • †

      † P < 0.05 vs. admission value of each group.

PreviousNext
Back to top

In this Issue

August 2004, 53(8)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises
Frankie B. Stentz, Guillermo E. Umpierrez, Ruben Cuervo, Abbas E. Kitabchi
Diabetes Aug 2004, 53 (8) 2079-2086; DOI: 10.2337/diabetes.53.8.2079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Proinflammatory Cytokines, Markers of Cardiovascular Risks, Oxidative Stress, and Lipid Peroxidation in Patients With Hyperglycemic Crises
Frankie B. Stentz, Guillermo E. Umpierrez, Ruben Cuervo, Abbas E. Kitabchi
Diabetes Aug 2004, 53 (8) 2079-2086; DOI: 10.2337/diabetes.53.8.2079
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • ETV5 Regulates Hepatic Fatty Acid Metabolism Through PPAR Signaling Pathway
  • The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes
  • Depletion of Adipocyte Becn1 Leads to Lipodystrophy and Metabolic Dysregulation
Show more Pathophysiology

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.